Suchergebnisse - "Li, Shuyu"

PubPharm (9)

1

Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers

enthalten in: The oncologist | 2021

von Ayers, K. | Mullaney, T. | Zhou, X. | +22

2

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

enthalten in: BMC cancer | 2021

von Ayers, K. | Ma, M. | Debussche, G. | +11

3

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

enthalten in: BMC cancer | 2021

von Ayers, K. | Ma, M. | Debussche, G. | +11

4

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

enthalten in: Experimental hematology & oncology | 2017

von Li, S. | Martial, A. | Schrock, A. | +1

5

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

enthalten in: Experimental hematology & oncology | 2017

von Li, S. | Martial, A. | Schrock, A. | +1

6

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

enthalten in: Genome medicine | 2017

von Li, S. | Ma, M. | Li, H. | +6

7

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

enthalten in: Genome medicine | 2017

von Li, S. | Ma, M. | Li, H. | +6

8

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

enthalten in: Genome medicine | 2017

von Li, S. | Ma, M. | Li, H. | +6

9

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

enthalten in: Experimental hematology & oncology | 2017

von Li, S. | Martial, A. | Schrock, A. | +1

1
[1]